GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Black Diamond Therapeutics Inc (NAS:BDTX) » Definitions » Gross Property, Plant and Equipment

Black Diamond Therapeutics (Black Diamond Therapeutics) Gross Property, Plant and Equipment : $23.78 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Black Diamond Therapeutics Gross Property, Plant and Equipment?

Black Diamond Therapeutics's quarterly gross PPE declined from Sep. 2023 ($25.25 Mil) to Dec. 2023 ($24.51 Mil) and declined from Dec. 2023 ($24.51 Mil) to Mar. 2024 ($23.78 Mil).

Black Diamond Therapeutics's annual gross PPE stayed the same from Dec. 2021 ($31.11 Mil) to Dec. 2022 ($28.13 Mil) but then declined from Dec. 2022 ($28.13 Mil) to Dec. 2023 ($24.51 Mil).


Black Diamond Therapeutics Gross Property, Plant and Equipment Historical Data

The historical data trend for Black Diamond Therapeutics's Gross Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Black Diamond Therapeutics Gross Property, Plant and Equipment Chart

Black Diamond Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Property, Plant and Equipment
Get a 7-Day Free Trial 0.28 8.95 31.11 28.13 24.51

Black Diamond Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.28 26.62 25.25 24.51 23.78

Black Diamond Therapeutics Gross Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Black Diamond Therapeutics  (NAS:BDTX) Gross Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Black Diamond Therapeutics Gross Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Black Diamond Therapeutics's Gross Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Black Diamond Therapeutics (Black Diamond Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
One Main Street, 14th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-189 and BDTX-1535.
Executives
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Ra Capital Nexus Fund, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali Behbahani director, 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter Kolchinsky director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David M. Epstein director, officer: See Remarks OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Sergey Yurasov officer: CHIEF MEDICAL OFFICER C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310, SEATTLE WA 98102
Elizabeth Buck officer: CHIEF SCIENTIFIC OFFICER C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Erika Jones officer: SEE REMARKS C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Fang Ni officer: SEE REMARKS C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Wendy L Dixon director
Mark A. Velleca director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Brent Hatzis-schoch officer: See Remarks C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451